Noonan Syndrome Medication

Updated: May 18, 2020
  • Author: Margaret M McGovern, MD, PhD; Chief Editor: Luis O Rohena, MD, MS, FAAP, FACMG  more...
  • Print
Medication

Medication Summary

Growth hormone may be used to treat short stature associated with Noonan syndrome. A randomized, double-blind, multicenter trial from Japan, by Horikawa et al, reported that prepubertal children with Noonan syndrome–associated short stature can achieve increased height through a 208-week regimen of somatropin administered at doses of 0.033 mg/kg/day or 0.066 mg/kg/day. However, the report found that the higher dose had a greater effect on height, with the investigation revealing the drug to be well tolerated. [28, 29]

Next:

Growth Hormone

Class Summary

Physiologic replacement for conditions of growth hormone deficiency.

Somatropin (Norditropin)

Human growth hormone produced by recombinant DNA technology (mouse C127 cell line). Elicits anabolic and anticatabolic influence on various cells including: myocytes, hepatocytes, adipocytes, lymphocytes, and hematopoietic cells. Stimulates growth of linear bone, skeletal muscle, and organs. Exerts activity on specific cell receptors including insulinlike growth factor-1 (IGF-1). Indicated for short stature associated with Noonan syndrome.

Previous